Publications
TGFß in GI Fibrosis
Sáez-Borderías, A., T Van Kaem, J Alberti, P J Stiers, C Sabadie, R Van Heeswijk, T Senso, B Pampín, R Bosser, P Wiesel. AGMB-129, an investigational ALK5 inhibitor for the treatment of Fibrostenosing Crohn’s Disease (FSCD), shows gastrointestinal (GI) restricted pharmacokinetics (PK) and a favorable safety profile in healthy subjects. ECCO 2025 Poster Presentation , Berlin, Germany; February 19-22, 2025.
TGFß in IPF
TGFß in Liver Fibrosis
Toxicity of systemic TGFß blockade
HGF/ MET Pathway Overview
HGF/ MET Pathway in Disease
Disclaimer
The publications reflect historical data. Agomab does not warrant that these data are accurate, complete or up-to-date as of the date you access such publications. All Agomab product candidates mentioned in these publications are investigational in nature and have not been approved yet by any regulatory authority. Their efficacy and safety have not been established. The content of these publications is not intended for patients. Patients should always consult with a doctor or other healthcare professionals for medical advice or information about diagnosis and treatment.